This study evaluates the long-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in a large cohort of patients treated in Sweden from 2003 to 2004. Using data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the researchers analyzed 6033 patients with DES and 13,738 patients with BMS, focusing on the composite of death and myocardial infarction over a 3-year period. The results showed no significant difference in the composite outcome between the two groups at 3 years. However, after 6 months, patients with DES had a significantly higher event rate, with a 12.7 more events per 1000 patients per year. At 3 years, mortality was significantly higher in the DES group, with an adjusted relative risk of 1.18. The study concluded that DES were associated with an increased risk of death compared to BMS, particularly after 6 months, and highlighted the need for further large, randomized trials to assess the long-term safety of DES.This study evaluates the long-term outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in a large cohort of patients treated in Sweden from 2003 to 2004. Using data from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR), the researchers analyzed 6033 patients with DES and 13,738 patients with BMS, focusing on the composite of death and myocardial infarction over a 3-year period. The results showed no significant difference in the composite outcome between the two groups at 3 years. However, after 6 months, patients with DES had a significantly higher event rate, with a 12.7 more events per 1000 patients per year. At 3 years, mortality was significantly higher in the DES group, with an adjusted relative risk of 1.18. The study concluded that DES were associated with an increased risk of death compared to BMS, particularly after 6 months, and highlighted the need for further large, randomized trials to assess the long-term safety of DES.